PATENT ISIS-1169

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Cook, et al.

Serial No.: 08/117,363 Group Art Unit: 1809

Filed: September 3, 1993

Examiner: S. Houtteman

AMINE-DERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES

Assistant Commissioner

for Patents

20231 Washington, D.C.

## STATEMENT IN SUPPORT OF PETITION TO CORRECT INVENTORSHIP UNDER 37 C.F.R. 1.48(a)

Charles J. Guinosso hereby states that:

- An error has occurred in inventorship of the aboveidentified patent application.
- This error occurred without deceptive intention on my part.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this statement is directed.

Date: Dec 18,1997

55SIS-1169 01/12

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Cook, et al.

Serial No.: 08/117,363

Group Art Unit: 1809

Filed: September 3, 1993

Examiner: S. Houtteman

For: AMINE-DERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES

Assistant Commissioner for Patents Washington, D.C. 20231

CONSENT OF ASSIGNEE TO CORRECTION OF INVENTORS

ISIS Pharmaceuticals is the assignee of the above-captioned patent application. As an official empowered to act on behalf of the ISIS Pharmaceuticals, I hereby acknowledge that the ISIS Pharmaceuticals consents to the addition of Charles Guinosso as a co-inventor of the above-captioned patent application.

B. Lynne Parshall (Name)

Executive Vice President
/ (Title) //

(Signature)

nber 18, 199

(Date)